Mike McCully, Gate Neurosciences CEO
August 23, 2022 11:20 AM EDT
Startups

Dragged by PhI­II flop and shelved by Ab­b­Vie, a class of de­pres­sion drugs finds new life at start­up

Amber Tong

A month be­fore Al­ler­gan re­vealed that it would be bought out by Ab­b­Vie for $63 bil­lion, CEO Brent Saun­ders took a painful hit on one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times